Astex Aims To Make Cancer Drug Resistance Futile
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
“Using our drugs, we’re trying to facilitate the old drugs or help them work better longer,” Astex’s Lyons said. Astex, AstraZeneca and Novartis all presented data on compounds from Astex’s fragment-based drug discovery platform at the recent American Association for Cancer Research meeting in Washington, D.C.
You may also be interested in...
Deals Of The Week: Hunting For Dengue Fever Drugs Amid Climate Change
Plus news of deals between Sanofi and Pozen, Otsuka and Astex, Santhera and Takeda, Ultragenyx and Kyowa, Baxter and Coherus Biosciences, Novartis and Regenerex, and more.
Astex Finds A Suitable Home As Otsuka Subsidiary
The California/U.K.-based biotech has announced plans to be acquired by Japanese pharma Otsuka in a deal that will please shareholders and provide its suitor with a slew of revenue-generating opportunities including a mid-stage pipeline, a platform technology and royalty streams.
Astex Finds A Suitable Home As Otsuka Subsidiary
The California/U.K.-based biotech has announced plans to be acquired by Japanese pharma Otsuka in a deal that will please shareholders and provide its suitor with a slew of revenue-generating opportunities including a mid-stage pipeline, a platform technology and royalty streams.